PRESS-RELEASE ·Filed Jun 3, 2026
Press release · Announcement
Actionable Insight • Neutral
The meningioma cohort expansion is a modest pipeline de-risking event but remains early-stage. Monitor upcoming data readouts from Cohort 3 and future medical conference presentations for efficacy signals.
Final — all horizons settled through T+60d
CATX ▼ -10.67% at T+60d
NEUTRAL call -10.67% · α vs SPY -13.17% · entry $3.56 → $3.18
T+1d
-8.71%
call -8.71% · α -9.11%
$3.25
settled 5mo ago
T+5d
-17.13%
call -17.13% · α -13.32%
$2.95
settled 5mo ago
T+20d
+1.97%
call +1.97% · α +2.97%
$3.63
settled 4mo ago
T+60d
-10.67%
call -10.67% · α -13.17%
$3.18
settled 2mo ago
Price Chart
Loading chart...
Executive Summary
Perspective Therapeutics announced the first patient dosed with [212Pb]VMT-α-NET in a new meningioma cohort of its ongoing Phase 1/2a study.
Key Facts
- First meningioma patient dosed with [212Pb]VMT-α-NET in Phase 1/2a study (LEMONαDE cohort).
- Meningiomas account for ~40% of all CNS tumors in the U.S.; ~20% of cases are WHO grades 2/3 with limited options.
- Interim data from NET cohorts reported at ASCO 2026; efficacy data for remaining Cohort 2 and Cohort 3 patients are pending.
- Company is a radiopharmaceutical developer using 212Pb alpha-particle therapy; market cap ~$411M.
Financial Impact
No financial data provided; early-stage clinical milestone with no revenue or guidance.
Risk Factors
- Clinical trial risks: safety, efficacy, or enrollment delays could impair value.
- Competition from other radiopharmaceutical and targeted therapies for meningioma.
- Cash burn rate and need for future financing given pre-revenue status.
Market Snapshot
Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
90% bullish (20 analysts)
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3305882 |
24 reports for CATX
33% Hit rate @ T+20 Went positive at some point 3 of 5 best @ T+60▲ +5.76%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | 8-K | $1.61 | awaiting T+20 | — | $1.21 (−24.84%) |
Oct 8, 2026 18d ago | 8-K | $2.71 | awaiting T+20 | — | $1.21 (−55.35%) |
Oct 2, 2026 24d ago | Press Release | $2.76 | awaiting T+20 | — | $1.21 (−56.16%) |
Sep 14, 2026 6w ago | 8-K | $2.92 $2.52 | ▼ −13.70% | ▼ −15.96% | $1.21 (−58.56%) |
Sep 11, 2026 6w ago | Press Release | $2.81 $2.66 | ▼ −5.34% | ▼ −7.21% | $1.21 (−56.94%) |
Sep 8, 2026 6w ago | Insider Cluster | $2.99 $2.46 | ▼ −17.73% | ▼ −19.67% | $1.21 (−59.53%) |
Sep 4, 2026 7w ago | Insider Cluster | $3.12 $2.36 | ▼ −24.36% | ▼ −26.07% | $1.21 (−61.22%) |
Sep 4, 2026 7w ago | Insider Cluster | $3.12 $2.36 | ▼ −24.36% | ▼ −26.07% | $1.21 (−61.22%) |
Aug 10, 2026 11w ago | 8-K | $3.18 $2.99 | ▼ −5.97% | ▼ −4.92% | $1.21 (−61.95%) |
Jul 17, 2026 14w ago | Press Release | $2.99 $3.20 | ▲ +7.02% | ▲ +2.58% | $1.21 (−59.53%) |
Showing 10 of 24
US Market Status
Market Closed — Opens in 4h 33m
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers